Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06409637 | FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | not yet recruiting | Phase 1 / Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 |
| clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06407570 | Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment | not yet recruiting | — | 100 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT05859217 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1) | not yet recruiting | Phase 2 | 40 | Jun Zhang, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06329947 | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | not yet recruiting | Phase 2 | 37 | Rui-hua Xu, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer(QUEEN-Dream) | not yet recruiting | Phase 2 | 73 | Fudan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05921149 | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | not yet recruiting | N/A | 170 | Endeavor HealthOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06399172 | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy(OSPRItaly) | not yet recruiting | — | 50 | OncoSil Medical LimitedINDUSTRY | 0 | May 3, 2024 | clinicaltrials |
| NCT06370026 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06393543 | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis(STICRISC) | not yet recruiting | — | 600 | Radboud University Medical CenterOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT06394713 | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | May 1, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06383663 | Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast Cancer | not yet recruiting | N/A | 452 | Sun Yat-sen UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06390982 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06391905 | PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS | not yet recruiting | Phase 2 | 60 | Guangdong Provincial People's HospitalOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06255379 | Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 52 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 4 | 80 | Yang Jianjun, PhDOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06389500 | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06385808 | Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | not yet recruiting | N/A | 37 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 26, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06384300 | Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China | not yet recruiting | N/A | 5,000 | Peking UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06380348 | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | not yet recruiting | Phase 3 | 398 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Apr 23, 2024 | clinicaltrials |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | not yet recruiting | Phase 2 | 68 | Li HuipingOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06374901 | Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | not yet recruiting | Phase 2 | 134 | Xiangdong ChengOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375109 | PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC(NeoSCLC-001) | not yet recruiting | Phase 2 | 60 | Beijing Chest Hospital, Capital Medical UniversityOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06375317 | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | not yet recruiting | Phase 2 | 42 | Yehua ShenOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06375954 | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | not yet recruiting | N/A | 96 | Hospital Universitari de BellvitgeOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06373133 | SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 36 | West China HospitalOTHER | 0 | Apr 18, 2024 | clinicaltrials |
| NCT06369441 | Collection of Biological Specimens and Associated Health Information | not yet recruiting | — | 10,000 | Ovation.io, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | not yet recruiting | — | 260 | Peking University People's HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06366945 | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC | not yet recruiting | Phase 2 | 85 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06368934 | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | not yet recruiting | N/A | 326 | Huashan HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06360978 | Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | not yet recruiting | N/A | 225 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT05621824 | A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS | not yet recruiting | — | 900 | Peking Union Medical College HospitalOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 10, 2024source: clinicaltrials